Lv1
20 积分 2022-09-22 加入
Real-world evidence on utilization and clinical outcomes of efgartigimod in patients with generalized myasthenia gravis
2个月前
已关闭
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Is partial complement blockade enough in myasthenia gravis?
2个月前
已关闭
Successful treatment with eculizumab in refractory myasthenia gravis with both anti-AChR and anti-LRP4 antibodies: two case reports
2个月前
已完结
The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo
2个月前
已完结
Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations
2个月前
已完结
重症肌无力患者血清Ryanodine受体抗体与临床的相关性研究
2个月前
已完结
补体C5抑制剂治疗重症肌无力的研究进展
2个月前
已完结
International Journal of Clinical Transfusion Medicine Dovepress Comparison of liberal and restrictive blood transfusion: current insights into clinical outcomes
2个月前
已完结
皖公网安备34019202002308
